ANRONYQHealthcare·Biotechnology#190 in industry

Alto Neuroscience, Inc.

Reports in 17d· 2026-05-14

+58.3% · 90d

$24.27

-0.25 (-1.02%)

News

(1)

April 2026

Apr 1, 20263 weeks ago8-KHealthcare

Alto Neuroscience, Inc. — 8-K Filing

ANROAlto Neuroscience, Inc.

# 🧾 What This Document Is This is an 8-K filing, which is a report of major events that shareholders should know about. Today's filing announces important clinical trial results and a shift in the company's research priorities. It's like a significant progress report for investors. # 🏢 What The C

Read summaryView on SEC EDGAR

Key Data

Market Cap$850.7M

Open$24.55

Prev Close$24.52

Day Range$23.92 – $25.66

52W Range$2.12 – $28.44

Volume185,315

P/E (TTM)—

EPS$-2.19

Dividend Yield—

Beta2.06

Price Target$35.27(+45.3%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy10 analysts

Buy 9Hold 1Sell 0

About

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Healthcare · Biotechnology

68 employees

www.altoneuroscience.com